{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:58:53Z","timestamp":1791374333199,"version":"4.3.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacl.2025.10.065","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:57:48Z","timestamp":1761364668000},"page":"96-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evaluation of bempedoic acid use in patients with homozygous familial hypercholesterolemia"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3635-7506","authenticated-orcid":false,"given":"Bruce A.","family":"Warden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5154","authenticated-orcid":false,"given":"Paul Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.10.065_bib0001","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2025.10.065_bib0002","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.10.065_bib0003","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"European Heart J"},{"key":"10.1016\/j.jacl.2025.10.065_bib0004","unstructured":"Warden BA, Fazio S, Shapiro MD., et al., eds. Endotext. MDText.com, Inc. Copyright \u00a9 2000-2025, MDText.com, Inc.; 2000."},{"key":"10.1016\/j.jacl.2025.10.065_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0025-7125(16)31424-9","article-title":"The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy","volume":"66","author":"Goldstein","year":"1982","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jacl.2025.10.065_bib0006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jacl.2025.10.065_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029175","article-title":"Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry","volume":"12","author":"Cuchel","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.10.065_bib0008","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Therapy"},{"key":"10.1016\/j.jacl.2025.10.065_bib0009","series-title":"Prescribing Information. Nexletol (bempedoic acid)","year":"2024"},{"key":"10.1016\/j.jacl.2025.10.065_bib0010","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.10.065_bib0011","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jacl.2025.10.065_bib0012","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jacc.2021.09.004","article-title":"Familial hypercholesterolemia: JACC Focus Seminar 4\/4","volume":"78","author":"Brandts","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.10.065_bib0013","unstructured":"Sheldon K., President and CEO of Esperion, Esperion aligns with U.S. Food and Drug Administration to initiate phase 3 clinical trials of bempedoic acid in pediatric heterozygous and homozygous familial hypercholesterolemia. https:\/\/www.esperion.com\/news-releases\/news-release-details\/esperion-aligns-us-food-and-drug-administration-initiate-phase-3. Accessed June 5, 2025."},{"key":"10.1016\/j.jacl.2025.10.065_bib0014","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic Acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"Jama Cardiol"},{"key":"10.1016\/j.jacl.2025.10.065_bib0015","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of Bempedoic acid versus placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical Trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.jacl.2025.10.065_bib0016","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.jacl.2023.12.005","article-title":"Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials","volume":"18","author":"Duell","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.10.065_bib0017","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.10.065_bib0018","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaccas.2022.06.021","article-title":"Implementation of novel lipid therapies in a refractory heterozygous familial hypercholesterolemia patient with atherosclerotic disease","volume":"4","author":"Weintraub","year":"2022","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.jacl.2025.10.065_bib0019","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.10.065_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.10.065_bib0021","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2021.11.013","article-title":"Real-world utilization of bempedoic acid in an academic preventive cardiology practice","volume":"16","author":"Warden","year":"2022","journal-title":"J Clin Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425004817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:47:34Z","timestamp":1791373654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425004817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1933287425004817"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.065","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of bempedoic acid use in patients with homozygous familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.10.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}